The Globe and Mail reports in its Friday edition that TD Cowen analyst Vince Valentini has reaffirmed his "buy" call and $26 share target for Telus. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at 21.56. Mr. Valentini says in a note: "We believe management is highly motivated to deliver on asset sales, which in turn will lower interest costs, so FCF should be covering 100 per cent of the cash dividend by the end of 2027, even with only modest EBITDA growth. When investors realize that this is not a repeat of the lead up to the dividend cut at BCE (the post-lease payout ratio is nowhere near as high at Telus; much larger percentage of household passings already migrated to fibre from copper, which means capex can decline; and Telus has a revenue mix with more organic growth potential), then we expect a meaningful recovery in the share price. Even a 7-per-cent dividend yield (30 per cent above BCE's yield and almost double Rogers) would put Telus shares at $24. ... Not much has changed in our forecasts or outlook for Telus Health." Mr. Valentini remains "optimistic" about the growth prospects and potential valuation for its health division moving forward.